Fluma 150 mg (Capsule)

Unit Price: ৳ 20.00 (20's pack: ৳ 400.00)

Medicine Details

Vaginal Candidiasis
Oropharyngeal Candidiasis
Oesophageal Candidiasis
Tinea corporis/Tinea cruris/Tinea pedis/Other Tinea
Kerion
Pityriasis versicolor
Onychomycosis
Invasive candidal infections and cryptococcal infections (including meningitis)
Prevention of cryptococcal meningitis
Prevention of fungal infections in immunocompromised patients
Systemic Candidiasis and Cryptococcal infection
Superficial Candidiasis
Fungal urinary tract infections
Disseminated candidiasis
Prophylaxis for fungal infection in neutropenic cancer patients
Acute treatment of other systemic fungal infections such as coccidioidomycosis and histoplasmosis

150 mg single dose for Vaginal Candidiasis
200 mg in 1st day followed by 100 mg daily for 14 days for Oropharyngeal Candidiasis
200 mg in 1st day followed by 100 mg daily for 14-30 days for Oesophageal Candidiasis
150 mg weekly for 4-6 weeks for Tinea corporis/Tinea cruris/Tinea pedis/Other Tinea
50 mg daily for 20 days for Kerion
400 mg as a single dose for Pityriasis versicolor
150 mg weekly for 12 months for Onychomycosis
Orally or by IV infusion, 400 mg on first day then 200-400 mg daily for Invasive candidal infections and cryptococcal infections (including meningitis)
Orally or by IV infusion 200 mg daily for Prevention of cryptococcal meningitis
Orally or by IV infusion, 50-400 mg daily for Prevention of fungal infections in immunocompromised patients
1-2 mg/kg daily for Superficial Candidiasis in children over 1 year
3-6 mg/kg daily for Systemic Candidiasis & Cryptococcal infection in children

Increases prothrombin time after warfarin administration
Prolongs the serum half-life of concomitantly administered oral sulphonyl ureas
Increases plasma concentrations of fuconazole when co-administered with hydrochlorothiazide
Increases the level of phenytoin
Results in a decrease in the AUC and shorter half-life when co-administered with rifampicin
Affects the AUCs of ethinyl estradiol and levonorgestrel when combined with oral contraceptives
Slowly increases cyclosporin concentrations
No clinically significant impairment of fuconazole absorption when co-administered with food, cimetidine, antacids or following total body irradiation for bone marrow transplantation
Results in a decrease in the mean plasma clearance of theophylline

Adverse fetal effects seen in animals at high dose levels
Should not be used in pregnancy or in women of childbearing potential unless adequate contraception is employed

Abnormalities of hepatic, renal, haematological and other biochemical function tests observed in some patients
Rare cases of hepatic necrosis
Development of exfoliative cutaneous reactions
Not recommended for use during lactation
Unlikely to impair a patient's ability to drive or use machinery

Normal dose should be used in the elderly
Dosage intervals or daily dosage should be adjusted in patients with renal impairment
Excreted predominantly in the urine as unchanged drug

Supportive measures and symptomatic treatment with gastric lavage if necessary
Forced volume diuresis may increase the elimination rate
Three-hour session of haemodialysis decreases plasma levels by approximately 50%